Laurus Labs Ltd

Laurus Labs Ltd rose for a fifth straight session today. The stock is quoting at Rs 2374.8, up 5.83% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.72% on the day, quoting at 23102.8. The Sensex is at 74677.67, up 0.71%. Laurus Labs Ltd has added around 19.7% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has added around 3.43% in last one month and is currently quoting at 26710.8, up 1.88% on the day. The volume in the stock stood at 54.31 lakh shares today, compared to the daily average of 16.59 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 2378.3, up 5.46% on the day. Laurus Labs Ltd is up 149.02% in last one year as compared to a 10.18% fall in NIFTY and a 22.72% fall in the Nifty Pharma index.The PE of the stock is 139.01 based on TTM earnings ending June 26.

Laurus Labs Ltd share price gained 2.75% to Rs 2245.0 after the company's net profit surged by 20.65% to Rs 436.74 crore, while revenue from operations slightly gained 8.89% to Rs 2206.37 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, rising 4.44%. It has improved by 5.74% over last one week and gained upto 0.60% in last one month while the market capitalization of Laurus Labs Ltd has increased 13.73% and 23.62% in the same period respectively. Profit before tax (PBT) of Laurus Labs Ltd stood at Rs 591.82 crore in Q3 FY26, rallying 119.41% year-on-year, and surging by 22.95% quarter-on-quarter. EBITDA came in at Rs 737 crore, jumping 95.93% YoY and expanding by 17.20% sequentially. Total expenses inched up 4.73% to Rs 1583.46 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 900.69 crore, increasing 14.63% YoY, while employee benefits expense was at Rs 265.71 crore, ticking higher by 2.71% YoY. For the TTM ended FY26, revenue from operations surged 22.67% to Rs 6812.9 crore, while net profit soared by 151.08% to Rs 889.85 crore, compared to previous TTM. EBITDA jumped by 102914% to Rs 1722.76 crore, and PBT jumped 144.04% to Rs 1181.88 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 1623.5 crore in FY26, as against Rs 601.65 crore in FY25. Laurus Labs Ltd rallied 133.49% in last one year, significantly outperforming the benchmark BSE Sensex which has reduced by 12.76% during the same period.

Laurus Labs Ltd share price ticked higher by 2.11% to Rs 2184.95 after the company's net profit saw a strong growth of 20.65% to Rs 436.74 crore, while revenue from operations improved marginally 8.89% to Rs 2206.37 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, gaining 4.24%. It has improved by 3.87% over last one week and gained upto 0.06% in last one month while the market capitalization of Laurus Labs Ltd has inched up 9.36% and 20.31% in the same period respectively. Profit before tax (PBT) of Laurus Labs Ltd stood at Rs 591.82 crore in Q3 FY26, jumping 119.41% year-on-year, and rallying 22.95% quarter-on-quarter. EBITDA came in at Rs 737 crore, expanding by 95.93% YoY and surging by 17.20% sequentially. Total expenses saw a slight increase of 4.73% to Rs 1583.46 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 900.69 crore, advancing by 14.63% YoY, while employee benefits expense was at Rs 265.71 crore, easing 2.71% YoY. For the TTM ended FY26, revenue from operations jumped by 22.67% to Rs 6812.9 crore, while net profit jumped 151.08% to Rs 889.85 crore, compared to previous TTM. EBITDA soared by 102914% to Rs 1722.76 crore, and PBT witnessed a strong rise of 144.04% to Rs 1181.88 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 1623.5 crore in FY26, as against Rs 601.65 crore in FY25. Laurus Labs Ltd rallied 127.68% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 13.45% during the same period.

Laurus Labs Limited announced that its board of directors approved an interim dividend of Re. 1.00, or 50%, per equity share of Rs 2 each for the financial year ending March 31, 2027, with November 6, 2026, set as the record date and payment expected on or after November 19, 2026.

Laurus Labs Limited announced that its board approved the acquisition of 52% of the share capital of SI & C Resins Private Limited for a pre-money valuation of Rs 30 crore, involving a total investment of Rs 32.50 crore through the primary acquisition of 10,833 equity shares. SI & C Resins, incorporated in July 2026, specializes in manufacturing and supplying polymer and silica-based products for the chemical, pharmaceutical, and biotechnology industries, and the acquisition will be completed during the current financial year, subject to customary closing conditions.

Laurus Labs Limited announced that its board of directors approved the acquisition of 60% of the share capital of Galenvs Sciences Inc., a Canada-based contract research and development organization (CRO/CDMO), for a pre-money valuation of USD 3.50 million. The company will invest a total of USD 3.75 million, comprising a primary infusion of USD 2.75 million and a secondary acquisition of USD 1.00 million, with Galenvs operating as a subsidiary and its wholly-owned subsidiary, Galenvs Solutions Inc., becoming a step-down subsidiary of Laurus Labs.

Laurus Labs Ltd is up for a third straight session today. The stock is quoting at Rs 2182.3, up 1.88% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.19% on the day, quoting at 22705.75. The Sensex is at 73339.6, down 0.35%. Laurus Labs Ltd has gained around 10.27% in last one month. Meanwhile, Nifty Pharma index of which Laurus Labs Ltd is a constituent, has gained around 1.54% in last one month and is currently quoting at 26267.25, up 0.96% on the day. The volume in the stock stood at 13.42 lakh shares today, compared to the daily average of 15.92 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 2188.8, up 2.1% on the day. Laurus Labs Ltd is up 126.92% in last one year as compared to a 12.85% slide in NIFTY and a 18.23% slide in the Nifty Pharma index.The PE of the stock is 132.5 based on TTM earnings ending June 26.

Laurus Labs Limited has invested Rs 1,078,000,000 and acquired 107,800,000 equity shares in KRKA Pharma Private Limited through a rights issue, bringing its total shareholding to 262,150,000 shares, representing a 49% stake in the joint venture company between KRKA d.d., Novo mesto, Slovenia and Laurus Labs Limited.

Laurus Labs Limited will hold a board meeting on Thursday, October 29, 2026, to consider and approve the unaudited financial results for the quarter and half-year ended September 30, 2026, and a proposal for the payment of an interim dividend for fiscal year 2026-27. The company’s trading window for directors and designated persons has been closed since Thursday, October 1, 2026, and will remain closed until Saturday, October 31, 2026.

Laurus Labs Limited informed the BSE Limited and National Stock Exchange of India Limited that KFin Technologies Limited, its Registrar and Share Transfer Agent, has certified that details of dematerialized and rematerialized securities for the quarter ended September 30, 2026, have been furnished to stock exchanges, in compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.